Two hundred and fifty-eight patients affected by EpCAM+ epithelial tumor-related malignant ascites (129 recurrent ovarian cancer) were randomly assigned to receive paracentesis followed by four i.p. infusion of catumaxomab, in a ten-day period, or paracentesis alone. This evidence concerns the gene EPCAM and ovarian carcinoma.